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Statement of Purpose: Circulating tumor cells (CTCs) 
have been highly studied due to its implication in cancer 
dissemination and metastases. Thus, an approach capable 
of hindering their dissemination could help prevent 90% of 
cancer deaths (1). Labeled nanoparticles (NPs) have been 
proposed to track cells and monitor the efficiency of any 
new cancer therapy in real time. The association of NPs to 
a microfluidic device, such as Vena8 biochips (Figure 2), 
allows the accomplishment of functions in vitro that are not 
easily imaginable in conventional biological analysis (e.g., 
simulation of physiological flow and shear stress). This 
novel approach may expedite therapies’ validation and its 
successful translation into clinics. In this study, we aim to 
develop an improved platform composed of labeled 
dendrimer nanoparticles and a microfluidic device for real-
time monitoring of cancer cells fate. 
Methods: Carboxymethyl-chitosan/poly(amidoamine) 
(CMCht/PAMAM) dendrimer nanoparticles were 
synthetized (2), labeled with the fluorescent label probe 
Fluorescein-5(6)-isothiocyanate (FITC) and characterized 
using Transmission electron microscopy, Atomic force 
microscopy, Dynamic light scattering, and Differential 
scanning calorimetry. After culturing a variety of cancer 
cell types, including HeLa (Cervical Carcinoma), HCT-
116 (Colon Carcinoma) and U87MG (Glioblastoma), in the 
presence of these nanoparticles, cell viability and 
internalization efficiency in static (standard cultures) and 
dynamic (microfluidic cultures) conditions were 
investigated by MTS/DNA and flow cytometry as well as 
fluorescence microscopy. 
Results: Nanoparticles were characterized by several 
physicochemical techniques. Results suggest that the 
synthesis was successful and nanoparticles are round-
shaped with a mean size of 50 nm and a negative charge of 
-34.3 ± 3 (mV) at neutral pH. Regarding cell viability in 
static conditions, no cytotoxic effects were observed when 
comparing the controls (absence of NP) and NP at 0.5 
mg.mL-1. However, different responses were observed 
regarding the presence of dendrimer nanoparticles when 
comparing static to dynamic conditions, with a tendency 
towards higher sensitivity when subjected to confinement 
(Figure 1). The results were corroborated by flow 
cytometry analysis (7AAD marker). Regarding 
internalization efficiency, higher internalization rates of 
the nanoparticles were observed in dynamic conditions as 
compared to traditional static culturing conditions, 
showing once again the relevance of using a dynamic 
system for validation of new therapies. 
 
 
Figure 1. Cytotoxicity of CMCht/PAMAM over HCT-116, HeLa and U87MG 
human cancer cell lines in static and dynamic conditions. Assays were conducted to 
assess cytotoxicity/viability over the cells at a concentration of 0.5 mg.ml-1 at 
different time points (days 1 and 3) and it in static and dynamic conditions. (* 
indicates significant differences when comparing 0.5 mg.ml-1 to control (0 mg.ml-1) 
at each time point. Ф indicates significant differences when comparing controls from 
day 3 to day 1 to determine cell proliferation).   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Vena8 microfluidic biochip and pump (Cellix®, Irland). 
 
 
Conclusions:  This study provided proof-of-concept on the 
use of a platform composed of microfluidic chip together 
with fluorescence labeled dendrimer nanoparticles for the 
validation of new chemotherapeutic agents.  In fact, the 
results show different responses to the presence of 0.5 
mg.mL-1 dendrimer nanoparticles when comparing static to 
dynamic conditions. There is a clear tendency towards 
higher sensitivity when subjected to confinement, flow and 
shear stress (dynamic conditions). Moreover, the observed 
high internalization rates of the nanoparticles can be 
beneficial, making them excellent intercellular carrier of 
anti-cancer drugs. Thus, the microfluidics can enable the 
development of diagnostics platform and personalized 
therapies, as it opens the possibility to a valuable system to 
test and validate new chemotherapeutic agents  
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